Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Serum microRNA profiles in athyroid patients on and off levothyroxine therapy.

Massolt ET, Chaker L, Visser TJ, Gillis AJM, Dorssers LCJ, Beukhof CM, Kam BLR, Franssen GJ, Brigante G, van Ginhoven TM, Visser WE, Looijenga LHJ, Peeters RP.

PLoS One. 2018 Apr 12;13(4):e0194259. doi: 10.1371/journal.pone.0194259. eCollection 2018.

2.

Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.

Ten Kate FJC, Suzuki L, Dorssers LCJ, Dinjens WNM, Jones DTW, Nieboer D, Doukas M, Van Lanschot JJB, Wijnhoven BPL, Looijenga LHJ, Biermann K.

Oncotarget. 2017 Oct 24;8(61):104123-104135. doi: 10.18632/oncotarget.22021. eCollection 2017 Nov 28.

3.

Multiparameter Investigation of a 46,XX/46,XY Tetragametic Chimeric Phenotypical Male Patient with Bilateral Scrotal Ovotestes and Ovulatory Activity.

van Bever Y, Wolffenbuttel KP, Brüggenwirth HT, Blom E, de Klein A, Eussen BHJ, van der Windt F, Hannema SE, Dessens AB, Dorssers LCJ, Biermann K, Hersmus R, de Rijke YB, Looijenga LHJ.

Sex Dev. 2018;12(1-3):145-154. doi: 10.1159/000479946. Epub 2017 Sep 20.

4.

Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline.

Giannoulatou E, Maher GJ, Ding Z, Gillis AJM, Dorssers LCJ, Hoischen A, Rajpert-De Meyts E; WGS500 Consortium, McVean G, Wilkie AOM, Looijenga LHJ, Goriely A.

PLoS One. 2017 May 22;12(5):e0178169. doi: 10.1371/journal.pone.0178169. eCollection 2017.

5.

Imprints and DPPA3 are bypassed during pluripotency- and differentiation-coupled methylation reprogramming in testicular germ cell tumors.

Killian JK, Dorssers LC, Trabert B, Gillis AJ, Cook MB, Wang Y, Waterfall JJ, Stevenson H, Smith WI Jr, Noyes N, Retnakumar P, Stoop JH, Oosterhuis JW, Meltzer PS, McGlynn KA, Looijenga LH.

Genome Res. 2016 Nov;26(11):1490-1504. Epub 2016 Oct 20.

6.

Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.

van Agthoven T, Dorssers LC, Lehmann U, Kreipe H, Looijenga LH, Christgen M.

PLoS One. 2015 Aug 28;10(8):e0136845. doi: 10.1371/journal.pone.0136845. eCollection 2015.

7.

Genome wide DNA methylation profiles provide clues to the origin and pathogenesis of germ cell tumors.

Rijlaarsdam MA, Tax DM, Gillis AJ, Dorssers LC, Koestler DC, de Ridder J, Looijenga LH.

PLoS One. 2015 Apr 10;10(4):e0122146. doi: 10.1371/journal.pone.0122146. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132981.

8.

Seminoma and embryonal carcinoma footprints identified by analysis of integrated genome-wide epigenetic and expression profiles of germ cell cancer cell lines.

van der Zwan YG, Rijlaarsdam MA, Rossello FJ, Notini AJ, de Boer S, Watkins DN, Gillis AJ, Dorssers LC, White SJ, Looijenga LH.

PLoS One. 2014 Jun 2;9(6):e98330. doi: 10.1371/journal.pone.0098330. eCollection 2014.

9.

DMRforPairs: identifying differentially methylated regions between unique samples using array based methylation profiles.

Rijlaarsdam MA, van der Zwan YG, Dorssers LC, Looijenga LH.

BMC Bioinformatics. 2014 May 15;15:141. doi: 10.1186/1471-2105-15-141.

10.

Role of SOX2 in the etiology of embryonal carcinoma, based on analysis of the NCCIT and NT2 cell lines.

Eini R, Stoop H, Gillis AJ, Biermann K, Dorssers LC, Looijenga LH.

PLoS One. 2014 Jan 3;9(1):e83585. doi: 10.1371/journal.pone.0083585. eCollection 2014.

11.

Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.

Gillis AJ, Rijlaarsdam MA, Eini R, Dorssers LC, Biermann K, Murray MJ, Nicholson JC, Coleman N, Dieckmann KP, Belge G, Bullerdiek J, Xu T, Bernard N, Looijenga LH.

Mol Oncol. 2013 Dec;7(6):1083-92. doi: 10.1016/j.molonc.2013.08.002. Epub 2013 Aug 20.

12.

Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer.

Eini R, Dorssers LC, Looijenga LH.

Int J Dev Biol. 2013;57(2-4):319-32. doi: 10.1387/ijdb.130020re. Review.

13.

miMsg: a target enrichment algorithm for predicted miR-mRNA interactions based on relative ranking of matched expression data.

Rijlaarsdam MA, Rijlaarsdam DJ, Gillis AJ, Dorssers LC, Looijenga LH.

Bioinformatics. 2013 Jul 1;29(13):1638-46. doi: 10.1093/bioinformatics/btt246. Epub 2013 May 1.

PMID:
23640718
14.

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T.

Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.

15.

Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.

van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC.

Int J Cancer. 2012 Nov 1;131(9):1998-2007. doi: 10.1002/ijc.27489. Epub 2012 Mar 20.

16.

Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.

Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T.

J Cell Physiol. 2011 Jul;226(7):1741-9. doi: 10.1002/jcp.22503.

PMID:
21506106
17.

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC, van Agthoven T.

Br J Cancer. 2010 Oct 12;103(8):1284-91. doi: 10.1038/sj.bjc.6605884. Epub 2010 Sep 21.

18.

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.

Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.

Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.

19.

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.

van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, Sleijfer S, Foekens JA, Dorssers LC.

Endocr Relat Cancer. 2010 Feb 18;17(1):215-30. doi: 10.1677/ERC-09-0062. Print 2010 Mar.

20.

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC.

Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10.

21.

The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells.

Brinkman A, de Jong D, Tuinman S, Azaouagh N, van Agthoven T, Dorssers LC.

Breast Cancer Res Treat. 2010 Apr;120(2):401-8. doi: 10.1007/s10549-009-0403-4. Epub 2009 May 3.

PMID:
19412734
22.

Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality.

van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Brüggenwirth HT, Withagen-Hermans CJ, Collée JM, Joosse SA, Terlouw-Kromosoeto JN, Nederlof PM.

Genet Test Mol Biomarkers. 2009 Jun;13(3):399-406. doi: 10.1089/gtmb.2008.0155.

PMID:
19405878
23.

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.

van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC.

J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.

PMID:
19075277
24.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
25.

Anni 2.0: a multipurpose text-mining tool for the life sciences.

Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, Kors JA.

Genome Biol. 2008;9(6):R96. doi: 10.1186/gb-2008-9-6-r96. Epub 2008 Jun 12.

26.

Functional identification of genes causing estrogen independence of human breast cancer cells.

van Agthoven T, Veldscholte J, Smid M, van Agthoven TL, Vreede L, Broertjes M, de Vries I, de Jong D, Sarwari R, Dorssers LC.

Breast Cancer Res Treat. 2009 Mar;114(1):23-30. doi: 10.1007/s10549-008-9969-5. Epub 2008 Mar 21.

PMID:
18351453
27.

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.

Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC.

Endocr Relat Cancer. 2008 Mar;15(1):101-11. doi: 10.1677/ERC-07-0080.

28.

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.

Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):253-60. doi: 10.1007/s10549-008-9934-3. Epub 2008 Feb 26.

PMID:
18299979
29.

Text-derived concept profiles support assessment of DNA microarray data for acute myeloid leukemia and for androgen receptor stimulation.

Jelier R, Jenster G, Dorssers LC, Wouters BJ, Hendriksen PJ, Mons B, Delwel R, Kors JA.

BMC Bioinformatics. 2007 Jan 18;8:14.

30.

Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells.

Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC.

Mol Cancer Res. 2006 Jun;4(6):379-86.

31.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM.

J Clin Oncol. 2005 Feb 1;23(4):732-40.

PMID:
15681518
32.

Co-occurrence based meta-analysis of scientific texts: retrieving biological relationships between genes.

Jelier R, Jenster G, Dorssers LC, van der Eijk CC, van Mulligen EM, Mons B, Kors JA.

Bioinformatics. 2005 May 1;21(9):2049-58. Epub 2005 Jan 18.

PMID:
15657104
33.
34.

The prognostic value of BCAR1 in patients with primary breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202.

35.

Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.

Grebenchtchikov N, Brinkman A, van Broekhoven SP, de Jong D, Geurts-Moespot A, Span PN, Peters HA, Portengen H, Foekens JA, Sweep CG, Dorssers LC.

Clin Chem. 2004 Aug;50(8):1356-63.

36.

Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, Klijn JG, Geurts-Moespot A, Span PN, Foekens JA, Sweep CG.

Clin Chem. 2004 Aug;50(8):1445-7. Epub 2004 May 27. No abstract available.

37.

GO-Mapper: functional analysis of gene expression data using the expression level as a score to evaluate Gene Ontology terms.

Smid M, Dorssers LC.

Bioinformatics. 2004 Nov 1;20(16):2618-25. Epub 2004 May 6.

PMID:
15130934
38.

Mining microarray datasets aided by knowledge stored in literature.

Jelier R, Jenster G, Dorssers LC, Van Mulligen EM, Mons B, Kors JA.

AMIA Annu Symp Proc. 2003:879.

39.
40.
41.

Tamoxifen resistance in breast cancer: elucidating mechanisms.

Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA.

Drugs. 2001;61(12):1721-33. Review.

PMID:
11693462
42.

Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue.

van der Flier S, van der Kwast TH, Claassen CJ, Timmermans M, Brinkman A, Henzen-Logmans SC, Foekens JA, Dorssers LC.

Int J Biol Markers. 2001 Jul-Sep;16(3):172-8.

PMID:
11605729
43.

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.

Berns EM, van Staveren IL, Verhoog L, van de Ouweland AM, Meijer-van Gelder M, Meijers-Heijboer H, Portengen H, Foekens JA, Dorssers LC, Klijn JG.

Br J Cancer. 2001 Aug 17;85(4):538-45.

44.

BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas.

van der Flier S, Chan CM, Brinkman A, Smid M, Johnston SR, Dorssers LC, Dowsett M.

Int J Cancer. 2000 Sep 20;89(5):465-8.

45.

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA.

J Natl Cancer Inst. 2000 Jan 19;92(2):120-7.

PMID:
10639513
46.

BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.

Brinkman A, van der Flier S, Kok EM, Dorssers LC.

J Natl Cancer Inst. 2000 Jan 19;92(2):112-20.

PMID:
10639512
47.

Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.

Hoogeveen-Westerveld M, Hupkes PE, Doekharan D, Dorssers LC, van't Veer MB, van Belzen N.

Leukemia. 1998 Nov;12(11):1810-6.

PMID:
9823958
48.

Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

van Agthoven T, van Agthoven TL, Dekker A, van der Spek PJ, Vreede L, Dorssers LC.

EMBO J. 1998 May 15;17(10):2799-808.

49.

Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkins lymphoma.

van Belzen N, Hupkes PE, Doekharan D, Hoogeveen-Westerveld M, Dorssers LC, van't Veer MB.

Leukemia. 1997 Oct;11(10):1742-52.

PMID:
9324296

Supplemental Content

Loading ...
Support Center